An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site and overcomes previous limitations of known antibodies. This study, led by Professor Dr. Florian Klein and published in the journal Nature Immunology, opens up new avenues for the development of vaccines and therapeutics against HIV-1.